Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul

Organ trafficking, transplant tourism, and transplant commercialism, which threaten to undermine the practice of transplantation worldwide, were the focus of an international summit in Istanbul from April 30 to May 1, 2008. The meeting was convened by The Transplantation Society and the International Society of Nephrology. The meeting resulted in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism (webappendix), which aims to halt these unethical activities and to foster safe and accountable practices that meet the needs of transplant recipients while protecting donors.

The initial text of the declaration was prepared by a steering committee, which also invited medical and scientific professionals, representatives of governmental and social agencies, social scientists, legal scholars, and ethicists to participate in the meeting. None of the 152 participants from 78 countries was polled with respect to his or her opinion, practice, or philosophy before selection. The declaration was agreed by consensus among the summit’s participants.

For more than two decades, governments around the world have recognised the need to protect poor people from the exploitation inherent in organ sales. Yet, partly as a consequence of the widespread shortage of organs and the increasing ease of internet communication, organ trafficking and transplant tourism have become global problems. Vulnerable populations (such as illiterate and impoverished individuals, undocumented immigrants, prisoners, and political or economic refugees) in resource-poor countries are now a major source of organs for rich patient-tourists who are prepared to travel and can afford to purchase organs. WHO has estimated that about 10% of organ transplants around the world involve these unacceptable activities and in some countries the rate is much higher (Noël L, WHO, Geneva, Switzerland; personal communication). For example, by 2006, two-thirds of the 2000 kidney transplants in Pakistan were for foreign recipients.

An essential first step in combating such activities is to describe them precisely. The declaration clearly defines organ trafficking, transplant commercialism, and transplant tourism (panel). The declaration also proposes policies and principles of practice on the basis of the definitions: “Organ trafficking and transplant tourism violate the principles of equity, justice and respect for human dignity and should be prohibited. Because transplant commercialism targets impoverished and otherwise vulnerable donors, it leads inexorably to inequity and injustice and should also be prohibited.” To be effective, these prohibitions must include bans on all types of advertising (electronic and print), soliciting, or brokering for the purpose of transplant commercialism.

The declaration describes universal approaches for the provision of care for the living donor, and also emphasises the need for effective practices that support organ donation from dead donors. Reimbursement of the documented costs incurred during the evaluation and performance of the donor procedure is part of the legitimate expense of transplantation and does not constitute a payment for organs. Governments should ensure the provision of care and follow-up of living donors, which should be no less than the care and attention provided for transplant recipients. For example, the provision of disability, life, and health insurance related to the donation event is an essential part of providing care for the donor in countries without social insurance systems.

Countries from which transplant tourists originate, as well as those to which they travel to obtain transplants in Pakistan were for foreign recipients. For more than two decades, governments around the world have recognised the need to protect poor people from the exploitation inherent in organ sales. Yet, partly as a consequence of the widespread shortage of organs and the increasing ease of internet communication, organ trafficking and transplant tourism have become global problems. Vulnerable populations (such as illiterate and impoverished individuals, undocumented immigrants, prisoners, and political or economic refugees) in resource-poor countries are now a major source of organs for rich patient-tourists who are prepared to travel and can afford to purchase organs. WHO has estimated that about 10% of organ transplants around the world involve these unacceptable activities and in some countries the rate is much higher (Noël L, WHO, Geneva, Switzerland; personal communication). For example, by 2006, two-thirds of the 2000 kidney transplants in Pakistan were for foreign recipients.

An essential first step in combating such activities is to describe them precisely. The declaration clearly defines organ trafficking, transplant commercialism, and transplant tourism (panel). The declaration also proposes policies and principles of practice on the basis of the definitions: “Organ trafficking and transplant tourism violate the principles of equity, justice and respect for human dignity and should be prohibited. Because transplant commercialism targets impoverished and otherwise vulnerable donors, it leads inexorably to inequity and injustice and should also be prohibited.” To be effective, these prohibitions must include bans on all types of advertising (electronic and print), soliciting, or brokering for the purpose of transplant commercialism.
Transplants, are just beginning to address their respective responsibilities to protect their people from exploitation and to develop a national self-sufficiency in organ donation. Leadership and encouragement from transplant professionals would contribute greatly to governments taking effective action to adopt and then to enforce strong laws consistent with the declaration. Participants in the Istanbul meeting have already played major roles in the promulgation of such laws and regulations within the past 2 years in China, Pakistan, and the Philippines.

The implications of the declaration’s definitions, principles, and recommendations are profound. The declaration will reinforce the resolve of governments and international organisations to develop laws and guidelines to bring an end to wrongful practices. The declaration calls for transparent regulatory oversight—with international accountability—that ensures the safety and well-being of donors and recipients alike.

Still, more is needed from the transplant and medical communities. The Transplantation Society and the International Society of Nephrology have endorsed the declaration. The steering committee has created task forces to facilitate dissemination of the declaration to national health authorities and to supplement existing professional standards. Recommendations from these task forces ought to include cancelling the professional society membership of individuals who do not adhere to the principles of the declaration. Drug companies and other funding agencies ought to apply the declaration’s principles when supporting research and other clinical activities. Journals ought not to publish studies from individuals or groups who do not comply with the declaration.

The legacy of transplantation is threatened by organ trafficking and transplant tourism. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism aims to combat these activities and to preserve the nobility of organ donation. The success of transplantation as a life-saving treatment does not require—or justify—victimising the world’s poor people as the source of organs for the rich.

Steering Committee of the Istanbul Summit

dma@transplantation-soc.org

(Steering Committee: Mano Abbud-Filho, FAMERP and Institute of Urology and Nephrology, Sao Paolo; Mustafa Al-Mohanna, Middle East Society for Organ Transplantation, Kuwait City; Ali Abdulkareem Abbadl, Kidney Transplant Services, Sheikh Khalifa Medical City, Abu Dhabi; Mona Nasir Al-Rukhaimi, Renal Unit, Dubai Hospital, Dubai; Alireza Bagheri, Tehran University of Medical Sciences; M A Bakr, Urology & Nephrology Centre, Mansoura University, Mansoura; Antoine Barbari, Rafik Hariri University Hospital, Beirut; Alexander Capron, University of Southern California, Los Angeles; Jeremy R Chapman, The Transplantation Society and University of Sydney, William Couser, International Society of Nephrology, Seattle; Gabriel Danovitch, David Geffen School of Medicine at UCLA; Leonardo D De Castro, University of the Philippines, Quezon City; Francis J Delmonico, The Transplantation Society, Boston; Iraj Fazel, Academy of Medical Sciences, Tehran; Mehmet Haberal, Baskent University and Turkish Transplantation Society, Ankara; Vivekanand Jha, Postgraduate Institute of Medical Education and Research, Chandigarh; Eiji Kobayashi, Jichi Medical University, Tochigi; Norbert Lameire, University Hospital, Ghent; Aデraea Levin, University of British Columbia, Vancouver; Mahamane Kalil Maiga, University of Bamako; Dominique Martin, Centre for Applied Philosophy and Public Ethics, University of Melbourne; Marwan Masri, Asian Society of Transplantation, Beirut; Saraladevi Naicker, University of the Witwatersrand, Johannesburg; Luc Noёl, WHO, Geneva; S Adibul Hasan Razvi, Sindhi Institute of Urology and Transplantation, Karachi; Bernardo Rodriguez-Iturbe, International Society of Nephrology, Maracaibo; Mohamed H Sayegh, Harvard Medical School, Boston; Faisal Al Saheen, Saud Council for Organ Transplantation, Jeddah; A G Stephan, Nephrology Division, Rizk Hospital, Beirut; Anika Tibeal, Karolinska Institute, Stockholm; Matthew Kwock-Lung Tong, Princess Margaret Hospital, Hong Kong; and A Vathsala, National University of Singapore. The Istanbul Summit was supported by an unrestricted grant to The Transplantation Society from Astellas Pharmaceuticals. The members of the Steering Committee declare that they have no conflict of interest.


For over 60 years, vitamin K antagonists, such as warfarin, have been the only available oral anticoagulants. Although effective, these drugs are challenging to use. Dose requirements vary among patients and the anticoagulant response is unpredictable. Consequently, coagulation needs to be monitored and the dose frequently adjusted to ensure that a therapeutic level of anticoagulation is achieved. Such monitoring is inconvenient for patients and costly for health-care systems.